Journal of Applied Physiology Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Appl Physiol 104: 1101-1108, 2008. First published February 14, 2008; doi:10.1152/japplphysiol.00865.2007
8750-7587/08 $8.00
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
104/4/1101    most recent
00865.2007v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Almlén, A.
Right arrow Articles by Curstedt, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Almlén, A.
Right arrow Articles by Curstedt, T.

Surfactant proteins B and C are both necessary for alveolar stability at end expiration in premature rabbits with respiratory distress syndrome

Andreas Almlén,1 Guido Stichtenoth,1 Bim Linderholm,1 Marie Haegerstrand-Björkman,1 Bengt Robertson,1 Jan Johansson,2 and Tore Curstedt1

1Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm; and 2Department of Anatomy, Physiology and Biochemistry, Swedish University of Agricultural Sciences, Biomedical Centre, Uppsala, Sweden

Submitted 10 August 2007 ; accepted in final form 13 February 2008

Modified natural surfactant preparations, used for treatment of respiratory distress syndrome in premature infants, contain phospholipids and the hydrophobic surfactant protein (SP)-B and SP-C. Herein, the individual and combined effects of SP-B and SP-C were evaluated in premature rabbit fetuses treated with airway instillation of surfactant and ventilated without positive end-expiratory pressure. Artificial surfactant preparations composed of synthetic phospholipids mixed with either 2% (wt/wt) of porcine SP-B, SP-C, or a synthetic poly-Leu analog of SP-C (SP-C33) did not stabilize the alveoli at the end of expiration, as measured by low lung gas volumes of ~5 ml/kg after 30 min of ventilation. However, treatment with phospholipids containing both SP-B and SP-C/SP-C33 approximately doubled lung gas volumes. Doubling the SP-C33 content did not affect lung gas volumes. The tidal volumes were similar in all groups receiving surfactant. This shows that SP-B and SP-C exert different physiological effects, since both proteins are needed to establish alveolar stability at end expiration in this animal model of respiratory distress syndrome, and that an optimal synthetic surfactant probably requires the presence of mimics of both SP-B and SP-C.

pulmonary surfactant; respiratory distress syndrome; synthetic peptide



Address for reprint requests and other correspondence: T. Curstedt, Dept. of Molecular Medicine and Surgery, Section of Clinical Chemistry, Bldg. L2:03, Karolinska Univ. Hospital, SE-171 76 Stockholm, Sweden (e-mail: tore.curstedt{at}karolinska.se)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.